FIELD: molecular biology, immunology, pharmacy. SUBSTANCE: invention relates to a monoclonal antibody NMO1 that shows a specific immunoreactivity with respect to protein HIV-1 gp120 or gp160 and shows capability to neutralize in vitro infection of cells H9 by living strains of HIV-1. NMO1 antibodies are isolated by hybridoma cellular line ATCC N HB 10726. Invention proposes also pharmaceutical compositions that will use for treatment of patients with HIV-1 infection by passive immunization. EFFECT: enhanced effectiveness of antibody and cellular line isolated. 5 cl, 18 dwg, 5 tbl, 9 ex
| Title | Year | Author | Number |
|---|---|---|---|
| HUMANIZED ANTIBODY AND METHOD OF PREPARATION THEREOF, POLYNUCLEOTYL (VERSIONS), AND HYBRIDON CELL LINE (VERSIONS) | 1993 |
|
RU2134724C1 |
| METHOD OF MONOCLONAL ANTIBODY PREPARATION TO MONOCLONAL ANTIBODY TO THE PROTEIN OF HUMAN LYMPHOCYTE T4, CULTURING CELL OF HYBRIDOMA JTI -IF3 - A PRODUCER OF MONOCLONAL ANTIBODY TO MONOCLONAL ANTIBODY TO THE PROTEIN OF HUMAN LYMPHOCYTE T4, CULTURING CELL OF HYBRIDOMA JTI -IF3-E5 - A PRODUCER OF MONOCLONAL ANTIBODY TO MONOCLONAL | 0 |
|
SU1801117A3 |
| TREATMENT AND FUNCTIONAL CURE OF HIV-INFECTION WITH MONOCLONAL ANTIBODIES TO CD4 MEDIATING COMPETITIVE INHIBITION OF HIV ENTRY | 2014 |
|
RU2762315C2 |
| RECONSTRUCTED HUMAN ANTIBODIES SPECIFIC FOR INTERLEUKIN-8 | 1995 |
|
RU2159776C2 |
| HIV ANTIBODY COMPOSITIONS AND METHODS FOR THEIR APPLICATION | 2016 |
|
RU2757135C2 |
| NEUTRALISING ANTI-INFLUENZA A ANTIBODIES AND USES THEREOF | 2014 |
|
RU2683498C2 |
| NEUTRALIZING ANTIBODIES AGAINST THE INFLUENZA A VIRUS AND WAYS OF THEIR APPLICATION | 2014 |
|
RU2803850C2 |
| MONOCLONAL ANTIBODIES AGAINST HUMAN TIM-3 | 2019 |
|
RU2777336C1 |
| BTN2-SPECIFIC ANTIBODIES AND USE THEREOF | 2020 |
|
RU2821703C2 |
| NEUTRALIZING ANTIBODIES TO INFLUENZA B VIRUS AND THEIR APPLICATION METHODS | 2020 |
|
RU2784915C2 |
